Citations

Showing 10 of 108081 citations.

Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2
Schreiner, Teri , Wilson-Murphy, Molly , Mendelt-Tillema, Jan, Waltz, Michael , Codden, Rachel , Gorman, Mark , Krupp, Lauren , Lotze, Tim, Mar, Soe , Ness, Jayne , Roalstad, Shelly, Rose, John , Shukla, Nikita , Wheeler, Yolanda , Casper, T. Charles , Krupp, Lauren , Rensel, Mary R. , Chitnis, Tanuja , Schreiner, Teri , Shukla, Nikita Malani , Benson, Leslie, Goyal, Manu S. , Rodriguez, Moses , Waubant, Emmanuelle L.

Mayo Clinic

Multiple Sclerosis Journal | March 24, 2023 | Volume: 29 | Issue: 4-5 | Pages: 576-584

10.1177/13524585231151948 | PMID 36960480 Get It

Background: Pediatric patients with multiple sclerosis (POMS) and related disorders, clinically isolated syndrome (CIS), myelin oligodendrocyte glycoprotein antibody disorder (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD), are commonly treated with immunosuppressants. Understanding the impact of SARS-CoV-2 infection in patients may inform treatment decisions. Objective: Characterize SARS-CoV-2 infection prevalence and severity among a cohort of patients with POMS and related disorders, as well as the impact of disease-modifying therapies (DMTs). Methods: POMS and related disorders patients enrolled in a large, prospective registry were screened for COVID-19 during standard-of-care neurology visits. If confirmed positive of having infection, further analysis was undertaken. Results: Six hundred and sixty-nine patients were surveyed between March 2020 and August 2021. There were 73 confirmed COVID-19 infections. Eight of nine hospitalized patients (89%), and all patients admitted to the ICU were treated with B cell depleting therapy. The unadjusted odds ratio of hospitalization among those who tested positive of having had COVID-19 was 15.27 among those on B-cell-depleting therapy ( p = 0.016). Conclusions: B-cell-depleting treatment was associated with a higher risk of COVID-19, higher rates of hospitalization, and ICU admission, suggesting this therapy carries a higher risk of severe infection in POMS and related disorders.
Mechanical extraction of a pulmonary valve vegetation in a patient with endocarditis
Senapati, Sidhartha G, Sabbah, Michael S. , Pislaru, Sorin V. , Motiei, Arashk

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | March 23, 2023 | Volume: 24 | Issue: 7 | Pages: e110-e110

10.1093/ehjci/jead054 | PMID 37086035 Get It

Antibody-mediated interferences affecting cardiac troponin assays: recommendations from the IFCC Committee on Clinical Applications of Cardiac Biomarkers
Hammarsten, Ola , Warner, Janet , Lam, Leo , Kavsak, Peter A. , Aakre, Kristin M. , Collinson, Paul , Jaffe, Allan S. , Saenger, Amy K., Mills, Nicholas L. , Omland, Torbjørn , Ordóñez‐Llanos, Jordi , Apple, Fred S. , Aakre, Kristin M , Collinson, Paul O , Mills, Nicholas L , Lindahl, Bertil , Jaffe, Allan S. , Body, Richard

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | March 23, 2023 | Volume: 61 | Issue: 8 | Pages: 1411-1419

10.1515/cclm-2023-0028 | PMID 36952681 Get It

Abstract The International Federation of Clinical Chemistry Committee on Clinical Applications of Cardiac Biomarkers (IFCC C-CB) provides educational documents to facilitate the interpretation and use of cardiac biomarkers in clinical laboratories and practice. Our aim is to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay. Measurements of cardiac troponin (cTn) have a prominent place in the clinical work-up of patients with suspected acute coronary syndrome. It is therefore important that clinical laboratories know how to recognize and assess analytical issues. Two emerging analytical issues resulting in falsely high cTn concentrations, often several fold higher than the upper reference limit (URL), are antibody-mediated assay interference due to long-lived cTn-antibody complexes, called macrotroponin, and crosslinking antibodies that are frequently referred to as heterophilic antibodies. We provide an overview of antibody-mediated cTn assay interference and provide recommendations on how to confirm the interference and interpret the results.
An Improved Method for Estimating Nephron Number and the Association of Resulting Nephron Number Estimates with Chronic Kidney Disease Outcomes
Đenić, Aleksandar , Alexander, Mariam P., Wilson, Luke D., Augustine, Joshua J. , Luehrs, Anthony C. , Stegall, Mark D. , Kline, Timothy L. , Sharma, Vidit , Thompson, R. Houston, Alexander, Mariam P. , Alexander, Mariam P , Stegall, Mark D , Rule, Andrew D , Denic, Aleksandar , Mullan, Aidan F. , Augustine, Joshua , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | March 23, 2023 | Volume: 34 | Issue: 7 | Pages: 1264-1278

10.1681/asn.0000000000000124 | PMID 36958059 Get It

Significance Statement Nephron number currently can be estimated only from glomerular density on a kidney biopsy combined with cortical volume from kidney imaging. Because of measurement biases, refinement of this approach and validation across different patient populations have been needed. The prognostic importance of nephron number also has been unclear. The authors present an improved method of estimating nephron number that corrects for several biases, resulting in a 27% higher nephron number estimate for donor kidneys compared with a prior method. After accounting for comorbidities, the new nephron number estimate does not differ between kidney donors and kidney patients with tumor and shows consistent associations with clinical characteristics across these two populations. The findings also indicate that low nephron number predicts CKD independent of biopsy and clinical characteristics in both populations. Background Nephron number can be estimated from glomerular density and cortical volume. However, because of measurement biases, this approach needs refinement, comparison between disparate populations, and evaluation as a predictor of CKD outcomes. Methods We studied 3020 living kidney donors and 1354 patients who underwent radical nephrectomy for tumor. We determined cortex volume of the retained kidney from presurgical imaging and glomerular density by morphometric analysis of needle core biopsy of the donated kidney and wedge sections of the removed kidney. Glomerular density was corrected for missing glomerular tufts, absence of the kidney capsule, and then tissue shrinkage on the basis of analysis of 30 autopsy kidneys. We used logistic regression (in donors) and Cox proportional hazard models (in patients with tumor) to assess the risk of CKD outcomes associated with nephron number. Results Donors had 1.17 million nephrons per kidney; patients with tumor had 0.99 million nephrons per kidney. A lower nephron number was associated with older age, female sex, shorter height, hypertension, family history of ESKD, lower GFR, and proteinuria. After adjusting for these characteristics, nephron number did not differ between donors and patients with tumor. Low nephron number (defined by <5th or <10th percentile by age and sex in a healthy subset) in both populations predicted future risk of CKD outcomes independent of biopsy and clinical characteristics. Conclusions Compared with an older method for estimating nephron number, a new method that addresses several sources of bias results in nephron number estimates that are 27% higher in donors and 1% higher in patients with tumor and shows consistency between two populations. Low nephron number independently predicts CKD in both populations. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_06_22_JASN0000000000000124.mp3
Hemosuccus Pancreaticus: Diagnostic Pitfalls of a Rare Condition
Busebee, Bradley , AT, Kurdi, BR, Stultz, LN, Sayegh, Busebee, Brad , Kurdi, Ahmed T. , Stultz, Benjamin R. , Sayegh, Lea N. , Coelho–Prabhu, Nayantara

Mayo Clinic

ACG Case Reports Journal | March 23, 2023 | Volume: 10 | Issue: 3 | Pages: e01014

10.14309/crj.0000000000001014 | PMID 36998341 Get It

ABSTRACT The combination of cirrhosis and chronic pancreatitis is rare and poses increased risk of hemorrhage requiring close clinical monitoring. We present a patient with history of alcohol-associated cirrhosis and chronic pancreatitis who was admitted to the intensive care unit with clinical hemorrhage believed secondary to epistaxis. After initial delay, esophagogastroduodenoscopy ultimately found blood and clots evacuating through the ampulla consistent with hemosuccus pancreaticus confirmed with computed tomography angiography. The patient ultimately improved with coil and gel foam vascular embolization. This case highlights the dangers of early diagnostic closure and presents a rare finding of hemosuccus without pseudoaneurysm formation.
Interventional vs surgical procedures in localized/nonmetastatic insulinomas (ablation vs surgery)
Sada, Alaa , McKenzie, Travis J. , Vella, Adrian, Levy, Michael J. , Hálfdánarson, Þorvarður R. , Halfdanarson, Thorvardur R , Levy, Michael J.

Mayo Clinic

Endocrine-Related Cancer | March 23, 2023 | Volume: 30 | Issue: 6 | Pages: No page available

10.1530/erc-22-0362 | PMID 36952635 Get It

Localized insulinoma is an uncommon entity that can result in substantial morbidity due to the associated hypoglycemia. Recent studies have suggested an increase in the incidence of insulinoma in recent decades that may possibly be secondary to increased awareness, incidental diagnoses, and better diagnostic methods. Diagnosing and localizing insulinoma within the pancreas can be challenging, but advances in nuclear imaging may improve diagnostic accuracy. Delays in diagnosis are common, but once a localized insulinoma is diagnosed and appropriately treated, the long-term prognosis is excellent. Surgical resection is considered the standard of care management option for localized insulinoma, but tumor ablation with endoscopic ultrasound guidance has also been shown to be an effective and safe method for therapy.
Acute type A aortic dissection in adolescents and young adults under 30 years of age: demographics, aetiology and postoperative outcomes of 139 cases
Luehr, Maximilian , Yıldız, Murat , Ma, Wei‐Guo , Heck, Roland , Polycarpou, Andreas , Jassar, Arminder S. , Weiss, Gabriel , Hagl, Christian, Rega, Filip , Schachner, Thomas , Martens, Andreas , Corte, Alessandro Della , Osada, Hiroaki, Sun, Lizhong, Tsagakis, Konstantinos , Schoenhoff, Florian , Sun, Li-Zhong , Weiss, Gabriel , Schachner, Thomas , Martens, Andreas , Della Corte, Alessandro , Sun, Li-Zhong , Tsagakis, Konstantinos , Schoenhoff, Florian , Kreibich, Maximilian , Dohle, Daniel‐Sebastian

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | March 23, 2023 | Volume: 63 | Issue: 5 | Pages: No page available

10.1093/ejcts/ezad112 | PMID 36951534 Get It

Abstract OBJECTIVES The prevalence and aetiology of acute aortic dissection type A (AADA) in patients ≤30 years is unknown. The aims of this clinical study were to determine the prevalence and potential aetiology of AADA in surgically treated patients ≤30 years and to evaluate the respective postoperative outcomes in this selective group of patients in a large multicentre study. METHODS Retrospective data collection was performed at 16 participating international aortic institutions. All patients ≤30 years at the time of dissection onset were included. The postoperative results were analysed with regard to connective tissue disease (CTD). RESULTS The overall prevalence of AADA ≤30 years was 1.8% (139 out of 7914 patients), including 51 (36.7%) patients who were retrospectively diagnosed with CTD. Cumulative postoperative mortality was 8.6%, 2.2% and 1.4%. Actuarial survival was 80% at 10 years postoperatively. Non-CTD patients (n = 88) had a significantly higher incidence of arterial hypertension (46.6% vs 9.8%; P &lt; 0.001) while AADA affected the aortic root (P &lt; 0.001) and arch (P = 0.029) significantly more often in the CTD group. A positive family history of aortic disease was present in 9.4% of the study cohort (n = 13). CONCLUSIONS The prevalence of AADA in surgically treated patients ≤30 years is &lt;2% with CTD and arterial hypertension as the 2 most prevalent triggers of AADA. Open surgery may be performed with good early results and excellent mid- to long-term outcomes.
Progressive basal ganglia damage and EE‐SWAS in a patient with a VPS13D pathogenic variant
Nordli, Douglas R. , Galán, Fernando , Galan, Fernando N , Nordli Iii, Douglas R

Mayo Clinic

Epileptic Disorders | March 23, 2023 | Volume: 25 | Issue: 1 | Pages: 117-119

10.1002/epd2.20031 | PMID 36951159 Get It

Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease
Akhiyat, Nadia , Lasho, Terra, Ganji, Morsaleh , Toya, Takumi , Shi, Chang‐Xin, Chen, Xianfeng , Braggio, Esteban , Ahmad, Ali , Stewart, Keith, Finke, Christy M. , Lerman, Lilach O. , Patnaik, Mrinal M. , Lerman, Lilach O , Lerman, Amir , Braggio, Esteban , Toya, Takumi , Corban, Michel , Fernandez, Jenna , Xie, Zhuoer , Lerman, Amir

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | March 23, 2023 | Volume: 43 | Issue: 5 | Pages: 774-783

10.1161/atvbaha.122.318928 | PMID 36951061 Get It

Background: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is a risk factor for cardiovascular disease. The relationship between CHIP and coronary microvascular dysfunction (CMD) is unknown. The current study examines the association between CHIP and CH with CMD and the potential relationships in risk for adverse cardiovascular outcomes. Methods: In this retrospective observational study, targeted next-generation sequencing was performed for 177 participants with no coronary artery disease who presented with chest pain and underwent routine coronary functional angiogram. Patients with somatic mutations in leukemia-associated driver genes in hematopoietic stem and progenitor cells were examined; CHIP was considered at a variant allele fraction ≥2%; CH was considered at a variant allele fraction ≥1%. CMD was defined as coronary flow reserve to intracoronary adenosine of ≤2. Major adverse cardiovascular events considered were myocardial infarction, coronary revascularization, or stroke. Results: A total of 177 participants were examined. Mean follow-up was 12±7 years. A total of 17 patients had CHIP and 28 had CH. Cases with CMD (n=19) were compared with controls with no CMD (n=158). Cases were 56±9 years, were 68% women, and had more CHIP (27%; P =0.028) and CH (42%; P =0.001) than controls. CMD was associated with independent risk for major adverse cardiovascular events (hazard ratio, 3.89 [95% CI, 1.21–12.56]; P =0.023), and 32% of this risk was mediated by CH. The risk mediated by CH was ≈0.5× as large as the direct effect of CMD on major adverse cardiovascular events. Conclusions: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.
Changes in Cardiovascular Health Across Midlife and Late-Life and Magnetic Resonance Imaging Markers of Cerebral Vascular Disease in Late-Life
Sedaghat, Sanaz , Ji, Yuekai, Empana, Jean‐Philippe , Hughes, Timothy M. , Mosley, Thomas H. , Griswold, Michael , Jack, Clifford R. , Lutsey, Pamela L. , Mosley, Thomas H. , Gottesman, Rebecca F , Jack, Clifford R , Lutsey, Pamela L , van Sloten, Thomas T , Gottesman, Rebecca F.

Mayo Clinic

Stroke | March 23, 2023 | Volume: 54 | Issue: 5 | Pages: 1280-1288

10.1161/strokeaha.122.041374 | PMID 36951053 Get It

Background: Cardiovascular health may be used for prevention of cerebral vascular disease; however, data on the association of cardiovascular health across midlife and late-life with late-life cerebral vascular disease are lacking. Our aim was to examine whether midlife or late-life cardiovascular health as well as changes of cardiovascular health within midlife and between midlife and late-life were associated with prevalence of magnetic resonance imaging markers of cerebral vascular disease at late-life. Methods: Prospective cohort study including 1638 participants from the Atherosclerosis Risk in Communities Study who took part in 2 visits at midlife (mean ages, 53 and 59 years), and a late-life visit (mean age, 76 years). A cardiovascular health Life’s Simple 7 score (range, 0–12/0–14, depending on diet availability) including 6 out of 7 items was calculated at each visit, with weight assigned to each item as poor (0), intermediate (1), or ideal (2). Participants underwent 3T brain magnetic resonance imaging scans in late-life visit. Outcomes were white matter hyperintensity volume, microbleeds, and lacunar, subcortical, and cortical infarcts at late-life. Linear and logistic regression models were used to assess the associations of cardiovascular health in midlife and late-life, and improvement of cardiovascular health within midlife, and from midlife to late-life with magnetic resonance imaging markers of cerebral vascular disease, adjusting for potential confounders. Results: A higher cardiovascular health in midlife, improvement of cardiovascular health within midlife, higher cardiovascular health at late-life, and improvement of cardiovascular health from midlife to late-life were associated with a lower prevalence of cerebral vascular disease markers. For example, improvement in cardiovascular health (per point) from midlife to late-life was associated with smaller white matter hyperintensity volume (β, −0.07 [95% CI, −0.10 to −0.04]) and lower odds of microbleeds (odds ratio, 0.93 [0.90–0.97]), lacunar (odds ratio, 0.93 [0.89–0.97]), subcortical (odds ratio, 0.93 [0.89–0.97]), and cortical infarcts (odds ratio, 0.92 [0.87–0.97]). Conclusions: Improving cardiovascular health within midlife and from midlife to late-life may prevent development of cerebral vascular disease.